and early identification of cardiac toxicity during and after treatment.
Spring 2012 Volume 9 • Number 4 imaging cell death or apoptosis. (2) Lastly, targeted cardiac imaging with Positron Emission Tomography (PET) may be able to detect early cell death due to doxorubicin.
Equilibrium Radionuclide Angiocardiography (ERNA)
ERNA, also known as a MUGA scan (multi-gated acquisition), involves tagging a patient's red blood cells with a radionuclide agent, technetium-99m, using an in-vivo or in-vitro technique. The tagged red blood cells are typically re-injected followed by image acquisition 15-30 minutes later depending on technique. Importantly, image acquisition is gated to the patient's cardiac rhythm at rest via an ECG monitor and 300-600 heartbeats are obtained on average The single largest study involving monitoring for cardiotoxicity involved serial ERNA or Single Photon Emission Computed Tomography (SPECT) imaging in 1 487 patients receiving doxorubicin. (4) Using this method of screening, 19% of patients were deemed to be at high risk for developing cardiotoxicity (defined as a baseline LVEF <50%, a drop in LVEF by ≥10% to a value <50% or cumulative doxorubicin doses ≥450 mg/m 2 ). Interestingly, clinical CHF improved in 87% of patients who were given routine therapy with digitalis, diuretics and/or vasodilators. Based on these high risk features, standard criteria were developed to aid in the management of screening for subclinical doxorubicin-associated cardiotoxicity with ERNA ( Table 1 ). The implementation of these guidelines resulted in a reduction in the incidence of heart failure due to cardiotoxicity. This was primarily due to the fact that these guidelines intended purpose was to allow the maximum dose of doxorubicin to be administered based on an individually determined threshold for subclinical cardiotoxicity. 
FIGURE 2:
Regions of interest drawn around the left ventricular blood pool cavity at end-diastole (ED, red arrow) and end-systole (ES, yellow arrow). The blue arrow represents the region of interest drawn inferior and lateral to the LV for the purposes of correction of background counts.
Based on the guidelines above, a more recent study demonstrated that 15% of patients receiving doxorubicin were deemed at high risk for CHF at some point during their therapy. (5) Furthermore, implementation of ERNA screening led to early discontinuation of treatment in 13% of patients due to criteria for cardiotoxicity, the majority of whom were asymptomatic. The same study found a net cost effectiveness of screening relative to estimated costs for the treatment of symptomatic CHF. This highlights the importance of routine screening, as many patients will demonstrate cardiotoxicity via a reduction in LVEF in the absence of overt heart failure symptoms.
While the accuracy and reproducibility of ERNA-based methods of LVEF quantification are established, the sensitivity and test characteristics for the prediction of CHF is suboptimal. (6) An abnormal LVEF at rest (<=45%) had a sensitivity of 53% and a specificity of 75% for detecting patients at moderate or high risk of developing CHF when compared to the gold standard of endomyocardial biopsy. The addition of exercise LVEF increased the sensitivity of detection of moderate or high-risk patients to 89% but lowered the specificity to 41%. Therefore, single resting LVEF measurements are not likely to possess the sensitivity required for widespread use as screening tests.
Despite certain pitfalls and concerns related to using changes in LVEF for prediction of subsequent cardiac dysfunction, ERNA continues to be a simple, effective and readily available approach for preventing cardiac morbidity and mortality.
Molecular imaging
Iodine-123-labelled metaiodobenzylguanidine (I-123 MIBG) is iodine labelled lab tracer that shares adrenergic neuroreceptor uptake storage and release mechanisms wino epinephrine. Myocardial uptake of I-123 MIBG reflects neuronal integrity and its release reflects adrenergic function. (7) There is animal and human evidence that reduced I-123 MIBG uptake occurs in doxorubicin cardiotoxicity, however this usually parallels changes in LV systolic function.
Indium-111 antimyosin (In-111 antimyosin) is a tracer that was developed for imaging of myocardial necrosis in a diverse set of cardiac pathologies such as myocarditis, transplant rejection and doxorubicin cardiotoxicity. In-111 antimyosin uptake occurs prior to changes in LV systolic function, however no long term studies exist and the specificity of this tracer for the prediction of cardiotoxicity is poor. (9, 10) Lastly, tracer availability, expense, and technical challenges limit its widespread clinical and research applicability. 
Guidelines for monitoring patients receiving doxorubicin
Perform baseline radionuclide angiocardiography at rest for calculation of left ventricular ejection fraction (LVEF) prior to administration of 100mg/m 2 of doxorubicin.
Subsequent studies are performed at least 3 weeks after the indicated total cumulative doses have been given, before consideration of the next dose.
Patients with normal baseline LVEF (≥50%)
Perform a second study after 250-350mg/m 2 .
Repeat study after 400mg/m 2 in patients with known heart disease, radiation exposure, abnormal ECG results, or cyclophosphamide therapy; or after 450mg/m 2 in the absence of any of these risk factors.
Discontinue doxorubicin therapy once functional criteria for cardiotoxicity develop, e.g. absolute decrease in LVEF ≥10% associated with a decline to a level ≤50%.
Patients with abnormal baseline LVEF (<50%)
Doxorubicin therapy should not be initiated with baseline LVEF ≤30%.
In patients with LVEF >30% and <50% sequential studies should be obtained prior to each dose.
Discontinue doxorubicin with cardiotoxicity: absolute decrease in LVEF ≥10% and/or fi nal LVEF ≤30%.
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Volume 9 • Number 4 Technetium-99m-labelled annexin V, an exciting radionuclide agent for imaging cell death, has been successfully evaluated in the detection of doxorubicin cardiotoxicity. (11) However, limited human experience means the future role for the precise evaluation, timing and detection of cardiotoxicity by this agent is undetermined.
Lastly, Herceptin (trastuzumab) labelled with Indium-111 (In-111-TZ) has been used to image metastatic breast cancer expressing the human epidermal growth factor receptor 2 (HER2) receptor. (12) A report of 20 patients with metastatic breast cancer expressing the HER-2 receptor demonstrated that 35% of patients had evidence of myocardial In-111-TZ uptake prior to administration of any chemotherapy and 86% of those patients with tracer uptake developed clinical heart failure, whereas none of the patients without uptake had adverse cardiac event. (13) These findings demonstrate the unique potential for targeted molecular imaging in providing useful therapeutic and prognostic information in patients being treated with potentially cardiotoxic agents. Larger studies are needed to confirm these findings and determine the effects of trastuzumab on cardiac events.
Cardiac PET imaging
The role of cardiac PET imaging has not been extensively investigated for the detection of cardiotoxicity. C-11 acetoacetate and C-11 acetate, markers of myocardial perfusion and oxidative metabolism, have been used and the former appears to be a more sensitive marker for the detection of cardiotoxicity and may be a promising alternative to ventriculography. (8) Cardiac PET is mostly used with fluorine-18-fluorodeoxyglucose (F-18 FDG) for the evaluation of malignant pericardial involvement, cardiac lymphoma staging and has largely focused on the diagnosis of metastatic lesions and response to chemotherapy in a wide range of malignancies.
ECHOCARDIOGRAPHY
Since the report that demonstrated a benefit of adjustment of doxorubicin therapy based on serial monitoring of LVEF employed ERNA, (6) this modality remains a mainstay of LV function assessment during cancer therapy. Nevertheless, echocardiography is preferred in many centres because of lack of radiation exposure, easier availability as well as the added benefit of assessing valvular dysfunction and pericardial disease which are typical sequelae of radiation therapy that is often used in combination with cardiotoxic chemotherapy. (14) Two-dimensional (2D) echocardiographic assessment imaging in the detection of cardiotoxicity. The first of these was a study comparing radionuclide imaging to echocardiography in 37 patients receiving doxorubicin or daunorubicin and found that echocardiography was less sensitive and specific. (17) In another study comparing radionuclide based assessment to early echocardiography in those receiving doxorubicin who had received endomyocardial biopsy and right heart catheterisation also found that echocardiography was less sensitive. (6) Both studies, however, were limited to M-mode based fractional shortening assessment, which cannot be extrapolated to modern 2D imaging technology.
More recent studies have demonstrated that despite good correlation between LVEF by echocardiography versus LVEF by ERNA (r = 0.81), intra-and inter-observer reproducibility is better for ERNA. (18) As a result, the authors proposed that ERNA should be the method of choice when precise reproducibility is important in patient management. Since relatively modest falls in EF by 10% or to a level less than 50% may trigger a discontinuation of potentially life-saving cancer therapy, precision should be considered a priority in monitoring for cardiotoxicity. When 2D-echocardiography and ERNA were utilised routinely before and after anthracycline use in a paediatric population, ERNA detected a significantly higher rate of cardiac dysfunction, and only ERNA detected diastolic dysfunction. (19) dimensions. Through acquisition of pyramidal-shaped volumes, 3D-echocardiography largely avoids this problem. By allowing precise manipulation of imaging planes to the long axis and short axis of the LV, 3D imaging also avoids pitfalls of foreshortening and oblique imaging. Furthermore, the intra-observer, inter-observer and inter-examination variability of 3D based measurements was small and lower than 2D. (25) Other groups have compared real-time 3D assessment of LVEF to cardiac MR and have similarly found consistent results. (20, (26) (27) (28) (29) In most cases, 3D measurements of LV volume have been found to slightly underestimate LV volumes when compared to CMR. This can be explained by the limited spatial resolution of certain 3D-echo datasets (Figure 4) , as well as difficulties in differentiating compacted myocardium from non-compacted trabeculae. Recommendations for tracing the endocardial border on 3D-echo to include trabeculae in the LV cavity have been proposed. (27) Since precision is critical to use of any imaging modality for serial assessment to guide therapeutic decisions and limits in the precision of LVEF assessment are the primary drawback of 2D-echo when compared to radionuclide imaging, 3D volumetric assessment of EF holds great promise as a safe, accessible and reliable technique for monitoring cardiotoxicity of cancer therapy.
Lastly, the most comprehensive study from a multi-modality perspective examined ERNA, 2D-echo, 3D-echo and cardiac magnetic resonance imaging (CMR) for the evaluation of cardiac function during trastuzumab therapy after doxorubicin. All patients received serial imaging using all 4 modalities at baseline, 6 and 12 months after beginning trastuzumab. They found a weak correlation between 2D-echo and CMR (r = 0.31 at baseline and r = 0.42 at 12mo), whereas the correlation for both 3D-echo and ERNA versus CMR were strong (r = 0.91 at baseline; r = 0.90 at 12 months', respectively. (20) A retrospective review of 217 consecutive patients who underwent pre-chemotherapy echocardiograms revealed relevant cardiac abnormalities that would not have been identified by radionuclide imaging such as aortic stenosis or moderate mitral regurgitation in 7.4% of patients, and led to a change of chemotherapy in 2.8%.
Based on this finding, this group proposed that echocardiography is more useful than radionuclide imaging; however, studies which demonstrate that the identification of these incidental findings leads to improved outcomes would be needed to support a change in 
Diastolic dysfunction
Various studies have explored changes in diastolic function before and after anthracycline exposure (30) (31) (32) (33) (34) in an attempt to provide a measure of risk. In patients receiving doxorubicin, the isovolumic relaxation period prolonged, early peak flow (E) was reduced and the ratio of early peak flow velocity to atrial peak flow velocity (E/A) also decreased significantly demonstrating worsening of diastolic indices when compared with age and sex matched controls or when compared with pre-treatment states. (31) It has also been found that a 37% increase in isovolumic relaxation time using Doppler echocardiography after doxorubicin was 78% sensitive and 88% specific for predicting a future drop in systolic function. (30) Baseline abnormal E/A ratio prior to treatment has also been associated with later development of cardiotoxicity. (32) These findings, however, are inconsistent. Another study found a relationship between anthracycline dose and poorer diastolic function indexes, but failed to find that diastolic dysfunction was helpful in predicting subsequent systolic dysfunction. (33) As a result, monitoring of diastolic function using transmitral flow velocities has failed to become an important component of cardiotoxicity monitoring.
Contractile reserve
Dobutamine stress echocardiography has been used in research settings to assess myocardial reserve in adults treated with anthracyclines, but worsening of systolic augmentation after anthracyclines has not been consistently found. (32, 35) One study, however, did note a smaller rise in peak E and fall in E/A ratio during dobutamine administration after anthracycline therapy and concluded that these findings represent the unmasking of early stage anthracycline cardiotoxicity. (36) Evaluation of contractile reserve by stress testing has also been investigated, specifically in a paediatric population. In children late onset cardiotoxicity is more common and techniques to identify those survivors of childhood cancer at risk for later clinical heart failure are needed. (37, 38) Exercise stress testing has been studied repeatedly in those treated with anthracyclines as children and was found to be helpful in identifying subclinical cardiotoxicity. (35, 39, 40) One study showed that children treated with anthracyclines had lower increases in cardiac index for similar levels of exercise when compared to age match controls. (39) More recently, it was shown that survivors of childhood cancer had lower percent thickening at end systole and reduced end-systolic wall stress after exercise compared to healthy controls. (35) At this time, however, a role for stress echocardiography in the routine clinical evaluation of patients treated with anthracyclines has not been defined.
Myocardial strain imaging
The echocardiographic technique with the greatest potential to improve our ability to identify those with early cardiotoxicity after treatment is strain imaging. Strain imaging previously used tissueDoppler techniques; however, due to several criticisms, particularly in relation to angle dependency, noise interference and substantial intra-and inter-observer variability, Speckle-tracking Echocardiography (STE) has emerged as an alternative technique in recent years. (41) With speckle tracking, natural acoustic reflectors within the myocardium also known as "speckles" are tracked from frame to frame to determine deformation (strain) and the speed of deformation (strain rate) ( Figure 5 ). For the LV, 3 normal strain components are used to describe normal deformation (longitudinal, circumferential and radial) ( Figure 6 ).
Several investigations have been published examining myocardial strain imaging after doxorubicin or trastuzumab treatment. In a murine model of cardiotoxicity, while LVEF and FS began to decline around day 5, strain rate imaging fell significantly as early as day 2
indicating the ability to detect earlier stages of dysfunctional myocardial mechanics. (42) In a similar study in humans changes in radial strain appeared earlier and were more pronounced than in Global and regional LV longitudinal and radial strain were significantly reduced in the absence of a significant change in LVEF in the first week after anthracycline therapy. (44) In a paediatric population receiving anthracyclines, early changes in LV longitudinal peak systolic strain occurred and correlated significantly with a subsequent change in EF. (45) Regarding strain imaging after treatment with trastuzumab patients who had received anthracyclines at least 6 months prior to trastuzumab still had a significant difference in mean 2D longitudinal strain rate at 3 to 12 months when compared to 0 to 3 months. (46) Collectively these data suggest that myocardial strain imaging parameters will be useful adjuncts to echocardiographic assessment of patients treated with cardiotoxic chemotherapy. As 3D speckle tracking becomes more prevalent, 3D strain assessments may further advance our ability to detect subclinical affects of cancer therapy on cardiac function.
CARDIAC MAGNETIC RESONANCE (CMR)
Cardiac magnetic resonance (CMR) is less frequently used as a non-invasive cardiac imaging tool to detect cardiotoxicity probably the longitudinal direction after 6 cycles of pegylated liposomal doxorubicin. (43) Radial deformation, a measure of myocardial wall thickening, may arise as a result of cardiotoxic damage to all 3 layers of the myocardium, unlike in ischaemic heart disease. 
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Spring 2012 Volume 9 • Number 4 because of the ubiquity of radionuclide and echocardiographic technologies. Nevertheless, due to its good temporal and spatial resolution, CMR is considered the gold standard for the assessment of LV function; (47) is exquisitely sensitive for the detection of unrecognised subendocardial myocardial infarctions by SPECT perfusion imaging; (48) and through T2-weighted imaging, has the unique potential to detect myocardial oedema. (49) Perhaps for these reasons, the American College of Cardiology & American Heart
Association Guidelines have recognised CMR as a viable modality for the screening of cardiotoxicity. (50) The utility of CMR for the assessment of trastuzumab cardiotoxicity was investigated in 10 breast cancer patients with suspected trastuzumab-induced cardiomyopathy. and all have shown correlation to its histopathologic features. (53) (54) (55) (56) Collectively, an absence of change of T1 values appears to indicate protection from the development of cardiotoxicity. Conversely, in those subjects with the highest increase in gadolinium-enhanced T1
values, an association with the development of congestive heart failure was found. Clearly larger studies with longer patient followup are required but for now T1 mapping for the detection of doxorubicin cardiomyopathy appears to hold much promise.
CARDIAC COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA)
Cardiac computed tomography angiography (CCTA) has emerged as a powerful tool for the non-invasive evaluation of the coronary arteries and an alternative to invasive diagnostic angiography. To our knowledge, there are no reports of CCTA for the evaluation of cardiotoxicity-induced subclinical LV systolic dysfunction.
However, there are data emerging on using CCTA for coronary artery evaluation in patients formerly treated for childhood malignancies, such as Hodgkin's lymphoma. (57) In this young asymptomatic patient cohort with a mean age of 20 years (range 6 to 43 years),
CCTA detected coronary artery disease in 16% of patients with 2 cases of severe, obstructive coronary artery plaque. In a smaller series of 9 patients formerly treated for Hodgkin's lymphoma, 8 out of 9 had coronary disease and coronary artery calcium scores higher than their aged matched peers. Of these asymptomatic indidivuals 2 out of 9 underwent revascularisation with coronary bypass surgery or angioplasty. (58) Larger prospective studies are required to better define the role of coronary CT angiography and calcium scoring and to ideally establish an algorithm for the evaluation and treatment of such patients.
CONCLUSIONS
Since the initial reports of doxorubicin cardiotoxicity nearly 40 years ago, multi-modality screening cardiovascular imaging techniques have changed dramatically. (59) Since the initial establishment of LV ejection fraction-based techniques such as ERNA, there have been continued advances in the fields of radionuclide imaging, echocardiography, magnetic resonance and computed tomography.
Ideally, cardiovascular medicine specialists need to interface in a multi-disciplinary approach to ensure optimal patient outcomes.
Much work has been completed, yet further investigation remains for cardiac imaging techniques to provide refinements in screening and ultimately to reduce short and long term cardiovascular morbidity and mortality that patients with cancer are exposed to.
Future screening for patients with cardiotoxicity will likely involve a multi-modality approach for improved risk stratification, prognostication and tailoring of individual chemotherapeutic regimens.
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